Turalio Alternatives Compared
Turalio (pexidartinib) | Xgeva (denosumab) | Denosumab |
|
---|
Turalio (pexidartinib) | Xgeva (denosumab) | Denosumab |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Giant Cell Tumor of Bone, Tenosynovial Giant Cell Tumor. Turalio may also be used for purposes not listed in this medication guide. |
Prescription only
Xgeva is an injection that is administered every four weeks to prevent bone fractures in people with certain types of cancer or to lower calcium levels in people with high calcium levels caused by... View more |
Prescription only
Denosumab is an injection that can be self-administered once every six months for the treatment of osteoporosis. It has been associated with an increased risk of fractures on discontinuation... View more |
Related suggestions Giant Cell Tumor of Bone
|
|||||||
More about Turalio (pexidartinib) | More about Xgeva (denosumab) | More about Denosumab | ||||||||
Ratings & Reviews | ||||||||||
Be the first to share your experience with this drug. |
Xgeva has an average rating of 5.6 out of 10 from a total of 10 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 40% reported a negative effect. |
Denosumab has an average rating of 3.0 out of 10 from a total of 399 ratings on Drugs.com. 17% of reviewers reported a positive effect, while 74% reported a negative effect. |
||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
View all Turalio side effects |
View all Xgeva side effects |
View all Denosumab side effects |
||||||||
Drug Class | ||||||||||
Generic Availability | ||||||||||
N/A |
N/A |
|||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Xgeva prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
Dosage Forms | ||||||||||
|
|
N/A |
||||||||
Brand Names | ||||||||||
N/A |
Other denosumab brands include: Bomyntra, Conexxence, Jubbonti, Osenvelt, Ospomyv, Prolia, Stoboclo, Wyost, Xbryk View more | Bomyntra, Conexxence, Jubbonti, Osenvelt, Ospomyv, Prolia, Stoboclo, Wyost, Xbryk, Xgeva View more | ||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
26.6 hours |
609.6 hours |
609.6 hours |
||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 651 drugs are known to interact with Turalio:
|
A total of 312 drugs are known to interact with Xgeva:
|
A total of 312 drugs are known to interact with Denosumab:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||
Disease Interactions | ||||||||||
First Approval Date | ||||||||||
August 02, 2019 |
June 01, 2010 |
N/A |
||||||||
WADA Class View classifications | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient Resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.